logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Hyperparathyroidism Secondary

    FiltersReset Filters
    12 results

    • calcitriol

      (Calcitriol)
      Sun Pharmaceutical Industries, Inc.
      Usage: Calcitriol is indicated for managing secondary hyperparathyroidism in predialysis patients with chronic renal failure, hypocalcemia in dialysis patients, and hypocalcemia related to postsurgical, idiopathic, or pseudohypoparathyroidism. It helps enhance calcium absorption and alleviate metabolic bone disease.

    • cinacalcet

      (Cinacalcet)
      Camber Pharmaceuticals, Inc.
      Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma, and severe hypercalcemia in primary hyperparathyroidism when surgery is not an option. Not indicated for non-dialysis CKD patients due to hypocalcemia risk.

    • cinacalcet

      (Cinacalcet)
      Aurobindo Pharma Limited
      Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, hypercalcemia in parathyroid carcinoma patients, and hypercalcemia in primary hyperparathyroidism when parathyroidectomy is not an option. Not for use in CKD patients not on dialysis due to hypocalcemia risk.

    • cinacalcet hydrochloride

      (cinacalcet hydrochloride)
      Slate Run Pharmaceuticals
      Usage: Cinacalcet tablets are indicated for treating secondary hyperparathyroidism in adults with chronic kidney disease on dialysis, and for hypercalcemia in adults with parathyroid carcinoma or primary hyperparathyroidism who cannot undergo parathyroidectomy. It is not recommended for CKD patients not on dialysis due to hypocalcemia risk.

    • doxercalciferol

      (Doxercalciferol)
      Meitheal Pharmaceuticals Inc.
      Usage: Doxercalciferol Injection is indicated for treating secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis.

    • doxercalciferol

      (Doxercalciferol)
      Alembic Pharmaceuticals Inc.
      Usage: Doxercalciferol Injection is indicated for treating secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis.

    • doxercalciferol

      (Doxercalciferol)
      Amneal Pharmaceuticals LLC
      Usage: Doxercalciferol injection is indicated for treating secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are undergoing dialysis.

    • paricalcitol

      (Paricalcitol)
      Amneal Pharmaceuticals LLC
      Usage: Paricalcitol injection is used to prevent and treat secondary hyperparathyroidism in patients aged 5 and older with chronic kidney disease on dialysis.

    • parsabiv

      (etelcalcetide)
      Amgen Inc
      Usage: PARSABIV is indicated for treating secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. It is not recommended for patients with parathyroid carcinoma, primary hyperparathyroidism, or those with chronic kidney disease not on hemodialysis.

    • rayaldee

      (calcifediol)
      OPKO Pharmaceuticals LLC
      Usage: RAYALDEE is indicated for treating secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and low serum 25-hydroxyvitamin D levels (<30 ng/mL). It is not intended for patients with stage 5 chronic kidney disease or those on dialysis.